Table 1.
Characteristics of study participants
| Variables | (N) Mean (SD) Median (Q1–Q3)a |
|---|---|
| 25(OH)D level continuous, ng/mL | (2063) 21.13 (8.83) 20.00 (15.00–25.83) |
| TC, mmol/L | (1566) 4.56 (1.00) 4.53 (3.89–5.16) |
| TG, mmol/L | (1566) 1.36 (0.88) 1.13 (0.82–1.65) |
| LDL, mmol/L | (1566) 2.71 (0.79) 2.66 (2.16–3.21) |
| HDL, mmol/L | (1566) 1.47 (0.33) 1.43 (1.23–1.66) |
| APO-A, g/L | (1566) 1.37 (0.27) 1.34 (1.18–1.53) |
| APO-B, g/L | (1566) 0.89 (0.23) 0.88 (0.73–1.04) |
| LPa, mg/L | (1566) 186.17 (166.01) 131.00 (73.25–243.00) |
| HCY, umol/L | (1567) 12.97 (6.37) 11.36 (9.27–15.04) |
| Ca, mmol/L | (2029) 2.26 (0.17) 2.26 (2.17–2.35) |
| β-CTX, ng/mL | (2045) 0.42 (0.30) 0.34 (0.19–0.59) |
| P1NP, ug/L | (2044) 50.44 (34.64) 43.00 (29.00–64.00) |
| Sex, N (%) | |
| Male | 333 (16.14%) |
| Female | 1730 (83.86%) |
| Age (years) | (2063) 68.51 (8.66) 68.00 (63.00–74.00) |
| Age (years), N (%) | |
| > 50, ≤ 70 | 1256 (60.88%) |
| > 70 | 807 (39.12%) |
| BMI (kg/m2), N (%) | |
| ≤ 18.5 | 99 (4.80%) |
| > 18.5, ≤ 23.9 | 1255 (60.83%) |
| > 23.9, ≤ 28 | 556 (26.95%) |
| > 28, ≤ 35 | 147 (7.13%) |
| > 35 | 6 (0.29%) |
| Season of blood collection, N (%) | |
| Spring (March, April and May) | 503 (24.38%) |
| Summer (June, July and August) | 509 (24.67%) |
| Autumn (September, October and November) | 608 (29.47%) |
| Winter (December, January and February) | 443 (21.47%) |
| Year of blood collection, N (%) | |
| 2015 | 21 (1.02%) |
| 2016 | 32 (1.55%) |
| 2017 | 48 (2.33%) |
| 2018 | 128 (6.20%) |
| 2019 | 458 (22.20%) |
| 2020 | 578 (28.02%) |
| 2021 | 705 (34.17%) |
| 2022 | 93 (4.51%) |
| Hypertension, N (%) | |
| No | 1420 (68.83%) |
| Yes | 643 (31.17%) |
| Diabetes, N (%) | |
| No | 1772 (85.89%) |
| Yes | 291 (14.11%) |
| Main diagnosis, N (%) | |
| OP without fractures | 1391 (67.43%) |
| OPF | 672 (32.57%) |
SD standard deviation, Q1 first quartile, Q3 third quartile, CI confidence interval, 25(OH)D 25-hydroxy vitamin D, TC total cholesterol, TG triglyceride, HDL high-density lipoprotein, LDL low-density lipoprotein, APO-A apolipoproteina, APO-B apolipoproteinb, LPa lipoproteina, HCY homocysteine, Ca calcium, BMI body mass index, β-CTX beta-C-terminal telopeptide of type I collagen, P1NP procollagen type I N-terminal propeptide, OP osteoporosis, OPF osteoporotic fracture
aFor continuous variables